Cambridge, UK, and Norwalk, Connecticut, USA, 12 August 2010. Astex Therapeutics, the UK-based biotechnology company developing targeted therapies for oncology and virology, and the Multiple Myeloma Research Consortium (MMRC) announced today the initiation of a Phase II clinical trial of the cyclin-dependent kinase (CDK) inhibitor, AT7519, to treat patients with relapsed or refractory multiple myeloma, an incurable blood cancer. The trial is designed to investigate both single agent and combination activity of AT7519 with bortezomib (Velcade®).
New report offers inside perspectives from industry leaders on the impact of whitespace radio, discussing market opportunities and new wireless products and services
Innovative Syringe developed by SCHOTT forma vitrum ag and Cambridge Consultants offers improved stability for highly sensitive drugs and gentler application for patients
Subscribe to our News RSS Feed
Founded in 1970 by
6 September 2010
The British Science Association in Cambridge
The British Science Association are looking for enthusiastic volunteers to join their new Cambridgeshire branch.
16 August 2010
Astex and Multiple Myeloma Research Consortium (MMRC) Announce Start of Phase II Clinical Study of AT7519 in Multiple Myeloma
Cambridge, UK, and Norwalk, Connecticut, USA, 12 August 2010. Astex Therapeutics, the UK-based biotechnology company developing targeted therapies for oncology and virology, and the Multiple Myeloma Research Consortium (MMRC) announced today the initiation of a Phase II clinical trial of the cyclin-dependent kinase (CDK) inhibitor, AT7519, to treat patients with relapsed or refractory multiple myeloma, an incurable blood cancer. The trial is designed to investigate both single agent and combination activity of AT7519 with bortezomib (Velcade®).
26 July 2010
ASIAN PROGRESS FOR OWLSTONE
A new order from a Japanese technology company for FAIMS development platforms has been received by Owlstone’s Cambridge UK laboratories.
CAMBRIDGE COMPANY WINS ‘OSCAR OF INNOVATION’
Owlstone Nanotech, Inc., in partnership with Pacific Northwest National Laboratory, has been selected as one of the 2010 R&D100 Award winners.
15 July 2010
Warning: ITC Group
A company by the name of ITC Group (http://www.itc-groupco.com/) are [...]
22 April 2010
Unlicensed whitespace frequencies could revolutionize wireless networks, experts say
New report offers inside perspectives from industry leaders on the impact of whitespace radio, discussing market opportunities and new wireless products and services
23 February 2010
Welcome to the new Cambridge Science Park website
As the Cambridge Science Park celebrates its 40th Anniversary in [...]
Cambridge Consultants celebrates 50 years of innovation
World leading product development company celebrates fifty years of technology innovation in 2010, its landmark year
Introducing the SCHOTT InJentle™ syringe – improved stability for sensitive drugs
Innovative Syringe developed by SCHOTT forma vitrum ag and Cambridge Consultants offers improved stability for highly sensitive drugs and gentler application for patients
Cambridge Consultants assists Consort Medical plc’s £16.8m acquisition of the Medical House plc
Expert appraisal of technology portfolio and due diligence supports significant [...]